Exabis Library
Welcome to the e-CCO Library!
OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP25: Biologics before surgery for IBD - Are they associated with post-operative infectious outcomes? Results from the National Surgical Quality Improvement Program Inflammatory Bowel Disease Collaborative
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: Final results from the GEMINI LTS study
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP26: The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in Ulcerative Colitis
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s Disease: Final results from the Phase 2 open-label extension study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP28: Gene expression (GE) values in a phase 2 trial of mirikizumab in Ulcerative Colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida Registry
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP30: Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP31: Meta–omics reveals microbiome driven proteolysis as a contributing ractor to severity of Ulcerative Colitis disease activity
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP33: Multi-omics analysis reveals specific bio-geographical and functional characteristics in Inflammatory Bowel Disease intestinal mucosa
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP34: VARSITY: A Double-Blind, Double-Dummy, Randomised, Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP35: Endoscopic and Deep Remission at 1 Year Prevents Disease Progression in Early Crohn’s Disease: Long-Term Data from CALM
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP37: Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP38: Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s Disease – A multicenter randomized controlled trial
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1